The Evaluating Liraglutide in Alzheimer’s Disease (ELAD) trial, a double-blind, placebo-controlled intervention on 204 patients with mild Alzheimer’s disease, found that those treated with the GLP1 Liraglutide experienced a slower decline in cognitive function and reduced brain atrophy compared to the placebo group [36]. This evidence concerns the gene GCG and Brain atrophy.